Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma
| Autor: | Xiangyan Jiang, Lei Zhao, Hongbin Li, Zeyuan Yu, Yong Ma, Xiao-Dong Jin, Yanbei Kuang, Jian-Li Wang, Huili Ye |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pancreatic ductal adenocarcinoma endocrine system diseases Transcription Genetic Bioinformatics Cell Cycle Proteins Adenocarcinoma S100A Malignancy S100 Calcium Binding Protein A6 Surgical oncology Cell Line Tumor Pancreatic cancer Internal medicine Databases Genetic Biomarkers Tumor Genetics medicine Humans S100 Calcium-Binding Protein A4 RNA Messenger Pancreas RC254-282 Annexin A2 Chemotactic Factors business.industry Research Calcium-Binding Proteins S100 Proteins Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cancer Patient survival Methylation Prognosis medicine.disease digestive system diseases Pancreatic Neoplasms Disease Progression Immunohistochemistry business Biomarkers Carcinoma Pancreatic Ductal |
| Zdroj: | BMC Cancer BMC Cancer, Vol 21, Iss 1, Pp 1-18 (2021) |
| ISSN: | 1471-2407 |
| Popis: | Background Pancreatic ductal adenocarcinoma (PDAC) remains a treatment-refractory malignancy with poor prognosis. It is urgent to identify novel and valid biomarkers to predict the progress and prognosis of PDAC. The S100A family have been identified as being involved in cell proliferation, migration and differentiation progression of various cancer types. However, the expression patterns and prognostic values of S100As in PDAC remain to be analyzed. Methods We investigated the transcriptional expressions, methylation level and prognostic value of S100As in PDAC patients from the Oncomine, GEPIA2, Linkedomics and cBioPortal databases. Real-time PCR was used to detect the expressions of S100A2/4/6/10/14/16 in four pancreatic cancer cell lines and pancreatic cancer tissues from PDAC patients undergoing surgery. To verify the results further, immunohistochemistry was used to measure the expression of S100A2/4/6/10/14/16 in 43 PDAC patients’ tissue samples. The drug relations of S100As were analyzed by using the Drugbank database. Results The results suggested that, the expression levels of S100A2/4/6/10/14/16 were elevated to PDAC tissues than in normal pancreatic tissues, and the promoter methylation levels of S100A S100A2/4/6/10/14/16 in PDAC (n = 10) were lower compared with normal tissue (n = 184) (P Conclusions Taken together, these results suggest that S100A2/4/6/10/14/16 might be served as prognostic biomarkers for survivals of PDAC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink